Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]
SEC Accession No. 0001072613-24-000898
Filing Date
2024-11-22
Accepted
2024-11-22 17:32:53
Documents
1
Group Members
ARCH VENTURE FUND X OVERAGE, L.P.ARCH VENTURE FUND X, L.P.ARCH VENTURE PARTNERS X OVERAGE, L.P.ARCH VENTURE PARTNERS X, L.P.ARCH VENTURE PARTNERS X, LLCARCH VENTURE PARTNERS XII, L.P.ARCH VENTURE PARTNERS XII, LLCKEITH CRANDELLKRISTINA BUROWROBERT NELSENS

Document Format Files

Seq Description Document Type Size
1 ARCH VENTURE FUND XII, L.P. - PRIME MEDICINE -- SCH 13D/A(#1) arch-sch13d_18909.htm SC 13D/A 435596
  Complete submission text file 0001072613-24-000898.txt   437591
Mailing Address 60 FIRST ST. CAMBRIDGE MA 02141
Business Address 60 FIRST ST. CAMBRIDGE MA 02141 617-465-0013
Prime Medicine, Inc. (Subject) CIK: 0001894562 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13D/A | Act: 34 | File No.: 005-93800 | Film No.: 241491086
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)

Mailing Address 8755 W. HIGGINS ROAD, SUITE 1025 CHICAGO IL 60631
Business Address 8755 W. HIGGINS ROAD, SUITE 1025 CHICAGO IL 60631 773-380-6600
ARCH Venture Fund XII, L.P. (Filed by) CIK: 0001906837 (see all company filings)

EIN.: 873448430 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13D/A